| Cause | Key Features |
|---|---|
| Acute MI / ACS (~70โ80%) | Most common cause. Large anterior STEMI, RV infarct. Emergent PCI/cath lab. SHOCK trial: early revascularization โ 6-month mortality SHOCK, 1999. |
| Acute decompensated HFrEF (~10โ15%) | End-stage HF on maximal GDMT. Progressive pump failure. Bridge to LVAD/transplant or palliative. |
| Acute valvular emergency (~5โ8%) | Acute severe MR (papillary muscle rupture post-MI), acute AR (endocarditis, aortic dissection), critical AS. Emergent surgical consult. |
| Fulminant myocarditis (~2โ5%) | Viral (Coxsackie, parvovirus B19), giant cell, eosinophilic. Young patient, rapid-onset HF. MRI if stable, biopsy if refractory. May need mechanical circulatory support (MCS) bridge to recovery. |
| Massive PE (~2โ3%) | RV failure from acute pressure overload. Not true "pump" failure -it's obstructive. tPA, catheter-directed therapy, or surgical embolectomy. |
| Cardiac tamponade (~1โ2%) | Beck's triad: hypotension, JVD, muffled heart sounds. Pulsus paradoxus > 10 mmHg. Emergent pericardiocentesis. |
| Arrhythmia-induced (~1โ2%) | Refractory VT/VF, complete heart block, tachycardia-mediated cardiomyopathy. Treat the rhythm -cardioversion, pacing, amiodarone. |
| Takotsubo (~1โ2%) | Apical ballooning, post-emotional/physical stress. Often mimics STEMI. Usually recovers in days to weeks. Supportive care. |
| Post-cardiotomy (~2โ6%) | Low CO syndrome post-cardiac surgery (CPB-related stunning). Milrinone or dobutamine. IABP/Impella if refractory. |
| Shock Type | CO | SVR | PCWP |
|---|---|---|---|
| Cardiogenic | โโ | โโ | โโ |
| Distributive (Septic) | โ or normal | โโ | Low/normal |
| Hypovolemic | โ | โ | โโ |
| Obstructive (PE/Tamponade) | โ | โ | Variable |
| Drug | Dose | Role | Notes |
|---|---|---|---|
| Norepinephrine (Levophed) 1ST LINE | 0.1โ1 mcg/kg/min | First-line vasopressor | Preferred over dopamine in CS. Increases MAP without excessive tachycardia. |
| Dobutamine (Dobutrex) | 2โ20 mcg/kg/min | Inotrope | โCO, โSVR. Use when MAP adequate but CO still low. Titrate to clinical response. Can cause arrhythmias. |
| Milrinone (Primacor) | 0.375โ0.75 mcg/kg/min | Inotrope/vasodilator | PDE3 inhibitor. Good in chronic HF (not beta-blocked). Avoid if hypotensive (vasodilatory). Renally cleared. |
| Vasopressin (Pitressin) | 0.03โ0.04 units/min | Vasopressor add-on | Nonadrenergic -useful adjunct to reduce catecholamine dose. Fixed dose. |
| Aspirin + Heparin | 325 mg PO + UFH per ACS protocol | ACS-associated CS | Antiplatelet + anticoagulation for PCI. Do not hold for hemodynamic instability. |
Patient: 59M, PMH HTN, smoking. Crushing chest pain x2h. ECG: ST elevation V1-V5. BP 78/50, HR 110, cold/clammy, JVP elevated.
Key findings: Lactate 5.8, troponin > 50, BNP 1200. Echo: anterior wall akinesis, EF ~15%. Cardiogenic shock from anterior STEMI.
Management:
Teaching point: The cath lab IS the treatment for MI-related CS. Every minute of delay = more infarct = deeper shock. Start pressors while preparing for PCI, not instead of PCI.
Patient: 72F, POD 5 from inferior STEMI. Sudden hypotension (BP 65/40), new loud holosystolic murmur at LLSB, acute respiratory distress.
Key findings: Echo: VSD with L-to-R shunt. PA catheter: O2 sat step-up from RA to RV. CI 1.6, PCWP 24.
Management:
Teaching point: Mechanical complications (VSD, papillary muscle rupture, free wall rupture) occur 3-7 days post-MI. Any acute deterioration in this window requires immediate echo. New murmur post-MI = VSD or acute MR until proven otherwise.
Patient: 45M with fulminant myocarditis. EF 5%, SCAI stage D. On max NE + dobutamine + vasopressin. Lactate rising 6 to 12.
Key findings: Refractory CS despite maximal medical therapy. Worsening multiorgan failure.
Management:
Teaching point: VA-ECMO provides support but increases LV afterload. Without LV venting, the LV distends, worsening ischemia and pulmonary edema. IABP provides insufficient support IABP-SHOCK II, 2012.